New chemotherapy agents in veterinary medicine.
Several anticancer drugs have been added to the therapeutic armamentarium in recent years. Some of these agents are traditional drugs with a long history of use in human oncology. Increased sophistication in clinical trial design in veterinary oncology has allowed the incorporation of agents previously viewed as excessively toxic. Other agents have been developed more recently. This article summarizes the veterinary experience with two older alkylating agents, lomustine and streptozocin, and newer compounds ifosfamide and gemcitabine. The published literature regarding veterinary use of these agents is limited, and the reader is advised to contact a veterinary oncologist for current guidelines when contemplating use of these agents.
Moore
Antony S
AS
Section of Oncology and Harrington Oncology Program, Tufts University School of Veterinary Medicine, 200 Westboro Road, North Grafton, MA 01536, USA. antony.moore@tufts.edu
Kitchell
Barbara E
BE
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D007069:Ifosfamide / Q000627:therapeutic use; D008130:Lomustine / Q000627:therapeutic use; D015080:Mesna / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D013311:Streptozocin / Q000627:therapeutic use; D019155:Veterinary Drugs; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D019155:Veterinary Drugs; D003841:Deoxycytidine; D013311:Streptozocin; D008130:Lomustine; D015080:Mesna; D007069:Ifosfamide; D000093542:Gemcitabine